FDA Approves New Test to Help Diagnose IBD, Show it is Different from IBS

FDA Approves New Test to Help Diagnose IBD, Show it is Different from IBS
Inova Diagnostics, a developer of autoimmune diagnostics, announced that the U.S. Food and Drug Administration has cleared QUANTA Lite Calprotectin Extended Range, an assay to diagnose  inflammatory bowel disease (IBD) and to help differentiate IBD from irritable bowel syndrome (IBS). QUANTA Lite is a quantitative enzyme-linked immunosorbent assay (ELISA) designed to detect concentrations of fecal

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *